Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Males and females~* Steroid-dependent or multirelapsing NS (defined on the basis of the occurrence of more than 2 relapses in the previous year in spite of steroid and/or other immunosuppressive therapy). Only patients reported to invariably relapse upon treatment tapering or withdrawal who are on stable (from at least 1 month) complete (\<0.3 g/24h for adults or \<4 mg/h/m2 for children) or partial (\<3.5 g/24h for adults or \<40 mg/h/m2 for children) remission of the NS will be included;~* Histological diagnosis of MCD or FSGS or mesangial proliferative GN;~* Written informed consent (or consent from parents or tutors for underage patients).~Exclusion criteria:~* Advanced renal failure (creatinine clearance less than 20 ml/min/1.73m2);~* Evidence of B or C virus infection;~* Refractory or persistent NS;~* Genetic mutations associated with intrinsic abnormalities of the glomerular barrier that would hardly be affected by rituximab treatment;~* Pregnancy or lactating;~* Women of childbearing potential without following a scientifically accepted form of contraception;~* Legal incapacity;~* Evidence of an uncooperative attitude;~* Previous diagnosis of: intellectual disability/mental retardation, dementia, schizophrenia.~* Any evidence that patient will not be able to complete the trial follow-up.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Rituximab (375 mg/m2).

Based on this trial design, predict the completion outcome and termination type (if applicable).